NASDAQ:ELYM
Eliem Therapeutics
- Stock
Description
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase IIa clinical trial; and ETX-155 for...Show More
Earnings
Earnings per Share (Estimate*)
Revenue (Estimate*)
*Estimate based on analyst consensus